Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Colorcon
Medtronic
McKinsey
Boehringer Ingelheim

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Patent: 9,821,057

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,821,057
Title:Anti-IL-6 antibody for use in the treatment of cachexia
Abstract: The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient\'s survivability or quality of life will preferably be improved.
Inventor(s): Smith; Jeffrey T. L. (Bellevue, WA), Latham; John A. (Seattle, WA), Litton; Mark (Seattle, WA), Schatzman; Randall (Redmond, WA)
Assignee: ALDERBIO HOLDINGS LLC (Las Vegas, NV)
Application Number:14/672,543
Patent Claims:see list of patent claims

Details for Patent 9,821,057

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Novartis Pharmaceuticals Corporation ARZERRA ofatumumab Injection 125326 2009-10-26 ⤷  Free Forever Trial 2029-11-24
Novartis Pharmaceuticals Corporation ARZERRA ofatumumab Injection 125326 2011-04-01 ⤷  Free Forever Trial 2029-11-24
Novartis Pharmaceuticals Corporation KESIMPTA ofatumumab Injection 125326 2020-08-20 ⤷  Free Forever Trial 2029-11-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Harvard Business School
Moodys
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.